期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 125, 期 -, 页码 143-150出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2018.04.002
关键词
Circulating tumor cells; Liquid biopsy; Prognostic biomarker; Predictive biomarker; Circulating tumor DNA; Clinical utility; Clinical application
资金
- National Institutes of Health (NIH)/National Cancer Institute (NCI) [U54CA198999]
- NIH/NCI [U54 CA151652, R01 CA178748, R21 CA182322]
- NATIONAL CANCER INSTITUTE [R01CA178748, U54CA198999] Funding Source: NIH RePORTER
Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow. (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据